Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Pharma's Powerhouse | Fortrea's strong position in large pharma offsets biotech challenges, promising stable revenue and growth opportunities in a competitive CRO landscape |
Financial Crossroads | Explore Fortrea's revised guidance and long-term objectives, including targeted revenue growth and EBITDA margins, amid current industry headwinds |
Strategic Realignment | Delve into Fortrea's initiatives to streamline operations, reduce costs, and improve productivity as it transitions to full independence from Labcorp |
Market Valuation | Analyst price targets range from $21 to $36, reflecting varied perspectives on Fortrea's potential to overcome near-term challenges and capitalize on strengths |
Metrics to compare | FTRE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFTREPeersSector | |
---|---|---|---|---|
P/E Ratio | −8.9x | −6.1x | −0.7x | |
PEG Ratio | 0.02 | −0.09 | 0.00 | |
Price/Book | 1.3x | 2.3x | 2.6x | |
Price / LTM Sales | 0.7x | 2.9x | 3.2x | |
Upside (Analyst Target) | 15.8% | 27.6% | 46.4% | |
Fair Value Upside | Unlock | 12.4% | 6.9% | Unlock |